Part 3 - The Movement

Join Dr. Tania Small, head of Medical Affairs at Bristol Myers Squibb, for a special edition of DoctoRx Unscripted, focused on hypertrophic cardiomyopathy (HCM)—one of the most common inherited cardiac diseases and one of the most frequently missed. 

Part 2 - The Shift

Join Dr. Tania Small, head of Medical Affairs at Bristol Myers Squibb, for a special edition of DoctoRx Unscripted, focused on hypertrophic cardiomyopathy (HCM)—one of the most common inherited cardiac diseases and one of the most frequently missed. 

Part 1 - The Moment

Join Dr. Tania Small, head of Medical Affairs at Bristol Myers Squibb, for a special edition of DoctoRx Unscripted, focused on hypertrophic cardiomyopathy (HCM)—one of the most common inherited cardiac diseases and one of the most frequently missed. 
 
In Part 1, NFL tight end Tommy Sweeney shares his experience being diagnosed with HCM. He reflects on his personal journey— from diagnosis and treatment decision making to his return to the NFL with his condition appropriately treated and well managed. 
 
His story underscores a sobering reality: HCM can remain undetected even in individuals who receive frequent medical screenings, like elite athletes.  

Highlights include:

About the Experts

Dr. Paul Richardson

Dr. Paul Richardson is an internationally recognized visionary in hematology and oncology whose trailblazing research at Dana-Farber Cancer Institute and Harvard Medical School has driven therapeutic revolutions in multiple myeloma, transforming patient outcomes and defining today’s standards of care. In addition to his involvement in the approval of nearly every major therapy for the disease over the past two decades, he is also one of the most prolific and cited experts in the field, with nearly 500 original articles and 400 reviews.

Dr. Richardson is a paid consultant for BMS.

Dr. Joseph Mikhael

Dr. Mikhael was not compensated for his participation.

Dr. Mecide Gharibo

Dr. Mecide Gharibo is an innovative hematology leader whose passion for transforming patient care extends from academic clinical expertise at Rutgers Cancer Institute to launching breakthrough therapies as Global Head of Hematology at Bristol Myers Squibb. Renowned for advancing life-saving treatments and optimizing patient access, Dr. Gharibo’s clinical excellence and senior pharmaceutical leadership have fueled medical innovation and set new standards for care through a proven record of successful therapy approvals.

Dr. Gharibo is an employee of BMS.

Highlights include:

If you want to understand the science, urgency, and humanity driving today’s breakthroughs, this episode is your front-row seat to the bleeding edge of discovery.

About the Experts

Dr. Paul Richardson

Dr. Paul Richardson is an internationally recognized visionary in hematology and oncology whose trailblazing research at Dana-Farber Cancer Institute and Harvard Medical School has driven therapeutic revolutions in multiple myeloma, transforming patient outcomes and defining today’s standards of care. In addition to his involvement in the approval of nearly every major therapy for the disease over the past two decades, he is also one of the most prolific and cited experts in the field, with nearly 500 original articles and 400 reviews.

Dr. Richardson is a paid consultant for BMS.

Dr. Joseph Mikhael

Dr. Mikhael was not compensated for his participation.

Dr. Mecide Gharibo

Dr. Mecide Gharibo is an innovative hematology leader whose passion for transforming patient care extends from academic clinical expertise at Rutgers Cancer Institute to launching breakthrough therapies as Global Head of Hematology at Bristol Myers Squibb. Renowned for advancing life-saving treatments and optimizing patient access, Dr. Gharibo’s clinical excellence and senior pharmaceutical leadership have fueled medical innovation and set new standards for care through a proven record of successful therapy approvals.

Dr. Gharibo is an employee of BMS.

Dr. Tania Small sits down with Dr. Heinz-Josef Lenz, one of the world’s greatest minds in gastrointestinal medical research, for a thought-provoking conversation on the future of colorectal cancer (CRC) care. 

Together, they unpack the rising incidence of early-onset CRC and the factors driving the surge of new cases in younger patients. This conversation dives into cutting-edge innovations that are reshaping detection and treatment: 

But the conversation doesn’t stop at science. Together, they examine the influence of lifestyle, disparities in access, and patient-driven data on survival. 

If you're driving change in oncology, this episode offers practical insights on integrating molecular testing, rethinking prevention, and preparing for the innovations ahead. 

About Dr Heinz-Josef Lenz

Heinz-Josef Lenz, MD, is an award-winning trailblazer and mentor whose pioneering work in colorectal cancer gene regulation, drug resistance, early detection and surveillance has reshaped the field of oncology. He is the recipient of multiple prestigious honors, including the ASCO Young Investigator Award, Career Development Award and the USC Mentoring Award, celebrating his excellence in both research and mentorship. Dr Lenz also serves on national committees including SWOG, NCI Task Forces and advisory boards and has authored numerous peer-reviewed publications. 

Dr Lenz is a professor of medicine, Preventive Medicine and Cancer Biology J Terrence Lanni chair in Cancer Research. He is also deputy Cancer Center director at USC Norris and co-director of USC Brown Center for Cancer Drug Development. 

Dr. Heinz-Josef Lenz is a paid BMS consultant.

In this special edition of DoctoRx Unscripted, Dr. Tania Small sits down with three of the most visionary leaders in oncology, Dr. Lillian Siu, Dr. Fabrice André and Dr. Howard “Skip” Burris for a provocative conversation on data that has the potential to redefine the future of cancer care.

Join Dr. Tania Small, in a compelling 2-part episode featuring Dr. George Grossberg, a world-renowned geriatric psychiatrist who's been at the forefront of Alzheimer’s disease research and innovation for over 40 years. With over 400 papers to his name, Dr. Grossberg brings unparalleled insights into the disease. 

In part 2, they delve into groundbreaking science - from researching novel therapeutic targets and addressing Alzheimer’s psychosis to the power of patient-driven science in research and prevention. 

It is a forward-looking conversation that equips you with new cutting-edge insights for the future. 

Join Dr. Tania Small, in a compelling 2-part episode featuring Dr. George Grossberg, a world-renowned geriatric psychiatrist who's been at the forefront of Alzheimer’s disease research and innovation for over 40 years. With over 400 papers to his name, Dr. Grossberg brings unparalleled insights into the disease. 

In part 1, they uncover the subtle early signs of Alzheimer’s, the biomarker revolution, and tackle the challenges of health equity in Alzheimer’s care.  

It’s an insightful discussion that prepares you for future trends. 

What happens when someone in the grip of a psychotic break commits a crime? 

In this episode of DoctoRx Unscripted, host Dr. Tania Small sits down with renowned forensic psychiatrist Dr. Ilan Melnick to confront that dilemma head-on. 

Dr. Melnick directs a dignity-first program that blends comprehensive psychiatric treatment, cognitive-restoration therapy, trauma-informed support, and structured community re-entry. The outcomes are extraordinary: 0 percent recidivism and 90 percent sustained reintegration—results that upend long-held assumptions about severe mental illness, justice, and what true healing can look like. 

Together, Drs. Small and Melnick unpack how this model works, why it succeeds, and how clinicians can begin adapting its principles today. This conversation reveals what becomes possible when we treat the person behind the psychosis—with dignity, rigorous care, and a roadmap for real-world impact.